Impaired fasting glucose level as metabolic side effect of nilotinib in non-diabetic chronic myeloid leukemia patients resistant to imatinib

被引：55

作者：

Breccia, M. ^{[1
]}

Muscaritoli, M. ^{[2
]}

Gentilim, F. ^{[1
]}

Latagliata, R. ^{[1
]}

Carmosino, I. ^{[1
]}

Fanelli, F. Rossi ^{[2
]}

Alimena, G. ^{[1
]}

机构：

[1] Univ Roma La Sapienza, Dept Cellular Biotechnol & Hematol, Rome, Italy

[2] Univ Roma La Sapienza, Dept Clin Med, Rome, Italy

来源：

LEUKEMIA RESEARCH | 2007年 / 31卷 / 12期

关键词：

D O I：

10.1016/j.leukres.2007.01.024

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：1770 / 1772

页数：3

共 10 条

[1] Chronic myeloid leukaemia: an investigation into the role of Bcr-Abl-induced abnormalities in glucose transport regulation [J].

Barnes, K ;

McIntosh, E ;

Whetton, AD ;

Daley, GQ ;

Bentley, J ;

Baldwin, SA .

ONCOGENE, 2005, 24 (20) :3257-3267

[2]

Boren J, 2001, J BIOL CHEM, V276, P37747

[3] Imatinib mesylate may improve fasting blood glucose in diabetic Ph plus chronic myelogenous leukemia patients responsive to treatment [J].

Breccia, M ;

Muscaritoli, M ;

Aversa, Z ;

Mandelli, F ;

Alimena, G .

JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (22) :4653-4655

[4] AMN107, a novel aminopyrimidine inhibitor of Bcr-Abl, has in vitro activity against imatinib-resistant chronic myeloid leukemia [J].

Golemovic, M ;

Verstovsek, S ;

Giles, F ;

Cortes, J ;

Manshouri, T ;

Manley, PW ;

Mestan, J ;

Dugan, M ;

Alland, L ;

Griffin, JD ;

Arlinghaus, RB ;

Sun, T ;

Kantarjian, H ;

Beran, M .

CLINICAL CANCER RESEARCH, 2005, 11 (13) :4941-4947

[5] Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL [J].

Kantarjian, Hagop ;

Giles, Francis ;

Wunderle, Lydia ;

Bhalla, Kapil ;

O'Brien, Susan ;

Wassmann, Barbara ;

Tanaka, Chiaki ;

Manley, Paul ;

Rae, Patricia ;

Mietlowski, William ;

Bochinski, Kathy ;

Hochhaus, Andreas ;

Griffin, James D. ;

Hoelzer, Dieter ;

Albitar, Maher ;

Dugan, Margaret ;

Cortes, Jorge ;

Alland, Leila ;

Ottmann, Oliver G. .

NEW ENGLAND JOURNAL OF MEDICINE, 2006, 354 (24) :2542-2551

[6]

Manley P. W., 2005, BLOOD, P106

[7] AMN107: Tightening the grip of imatinib [J].

O'Hare, T ;

Walters, DK ;

Deininger, MWN ;

Druker, BJ .

CANCER CELL, 2005, 7 (02) :117-119

[8] AMN107 (nilotinib): a novel and selective inhibitor of BCR-ABL [J].

Weisberg, E. ;

Manley, P. ;

Mestan, J. ;

Cowan-Jacob, S. ;

Ray, A. ;

Griffin, J. D. .

BRITISH JOURNAL OF CANCER, 2006, 94 (12) :1765-1769

[9] Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl [J].

Weisberg, E ;

Manley, PW ;

Breitenstein, W ;

Brüggen, J ;

Cowan-Jacob, SW ;

Ray, A ;

Huntly, B ;

Fabbro, D ;

Fendrich, G ;

Hall-Meyers, E ;

Kung, AL ;

Mestan, J ;

Daley, GQ ;

Callahan, L ;

Catley, L ;

Cavazza, C ;

Mohammed, A ;

Neuberg, D ;

Wright, RD ;

Gilliland, DG ;

Griffin, JD .

CANCER CELL, 2005, 7 (02) :129-141

[10] OCT-1-mediated influx is a key determinant of the intraceflular uptake of imatinib but not nilotinib, (AMN107): reduced OCT-1 activity is the cause of low in vitro sensitivity to imatinib [J].

White, Deborah L. ;

Saunders, Verity A. ;

Dang, Phuong ;

Engler, Jane ;

Zannettino, Andrew C. W. ;

Cambareri, Antony C. ;

Quinn, Steven R. ;

Manley, Paul W. ;

Hughes, Timothy P. .

BLOOD, 2006, 108 (02) :697-704

← 1 →